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Spectacular Elevations of Serum Alkaline Phosphatase:
Clinical and Pathological Correlation
Roy B. Patton, M . D . *

The diseases responsible for extremely high serum alkaline phosphatase
aclivily
in 45 patients were proliferative hone disease (10 patients) and hepato-biliary
tract disease (35 patients). Conditions found in these patients that are not usually
thought to cause such high phosphatase levels were: drug-induced cholestasis (6
patients), non-malignant extra-hepatic bile duct obstruction (3 palienis). biliary
or portal cirrhosis (5 patients), and primary hyperparathyroidism
with generalized
osteitis fibrosa (I patient).

Alkaline phosphatase activity is frequently determined in the clinical laboratory with increases in the serum
content of this enzyme being commonly
associated with bone disease in which
there is formation of new bone tissue,
extra and intrahepatic biliary duct obstruction and parenchymatous liver
disease. Three other rather special conditions may be responsible for abnormal elevations of serum alkaline
phosphatase: (1) The placenta is rich
in an alkaline phosphatase and this
accounts for the modest increase in
the serum content of this enzyme in
women in the third trimester of pregnancy.' (2) Human albumin for injection is prepared at least in part from
placentas and persons receiving this
material may have markedly high phosphatase levels from this source.- (3)
Alkaline phosphatase production by a
malignant tumor has been reported in
a patient in whom the serum alkaline
phosphatase level was elevated.-'

porting laboratory; values above this
range are unusual. Recently 1 encountered a patient with serum alkaline
phosphatase levels of 73. 80 and 82
Bodansky units/100 ml. Since the reason for this was not immediately apparent. I was stimulated to find out how
often spectacularly high serum alkaline
phosphatase levels are found and, also,
to evaluate the clinical conditions associated with these high levels.
Materials and Methods
Records of the clinical chemistry
laboratory of the Henry Ford Hospital
were searched for patients having
serum alkaline phosphatase measurements of 50 or more Bodansky units/
100 ml during the period from April
1968 thru March 1969. During this
time 14,258 measurements of serum
alkaline phosphatase were made. Many
of these represented repeat examinations of the same patients.
The method is adapted for use in an
automatic analyzer and essentially is
that of King and Armstrong* with
modification. Results as determined
are thus in King-Armstrong units.
These are divided by a factor of 3.3

Increases in phosphatase activity are
usually in a range of two to ten times
the upper limit of normal for the re••'Department of Pathology
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Table
Disease processes responsible for extremely high alkaline
phosphatase activity in 45 patients.
Disease

Patients
10

Bone
Carcinoma of the prostate
with osteoblastic metastases
Paget's disease of bone
Primary hyperparathyroidism
with osteitis fibrosa
Carcinoma of the breast with
osteoblastic metastases
Liver and/or Bile Ducts

35

Primary or metastatic
ca rcinoma

21

Cirrhosis

5

Nonmalignant extra-hepatic
bile duct obstruction

3

Drug-induced cholestasis
and reported as Bodansky u n i t s . T h e
range of normal for adults is 1.5-4.0
Bodansky units/100 ml. When an abnormal value is discovered and there
is sufficient specimen, it is re-tested in
the chemistry laboratory for the abnormal constituent. The abnormal
value is not reported if the re-test does
not confirm it.
It is not possible precisely to convert
units of alkaline phosphatase activity
determined by a given method to units
in a different method. This is due
mainly to differences in substrate composition, incubation time, serum concentration and pH of the reaction mix-

ture, as well as to local laboratory
modifications of original methods.
Results
Forty-five patients with serum alkaline phosphatase measurements of 50
or more Bodansky units/100 ml were
found during the 12-month period of
study. In all of these patients at least
one other serum, assayed for this constituent, confirmed the high value.
Twenty-five of the 45 patients had
values between 50 and 70 units, 14
were between 70 and 100 units, and
six had more than 100 units, the highest
being 361 Bodansky units/100 ml. The
212
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clinical records of these patients were
examined in order to identify the
disease process accounting for the extremely high serum alkaline phosphatase. Table I shows the kinds of disease
found and the number of patients in
each group.
Proliferative bone disease was responsible for the high serum alkaline
phosphatase in ten patients, six of
whom had carcinoma of the prostate
gland with osteoblastic bone metastases. Only one of these patients was
jaundiced. In this patient, no obstructive disease and no evidence of
metastases in the liver were found during a common bile duct exploration.
The jaundice, which subsequently
cleared, may have been due to druginduced cholestasis. Two of the ten
patients had Paget's disease of bone,
but no evidence of liver disease. One
patient had a parathyroid adenoma
with hyperparathyroidism and generalized osteitis fibrosa. She was never
jaundiced and, at necropsy, there was
no evidence of liver disease." The tenth
patient had carcinoma of the breast
•with osteoblastic bone metastases.
Three liver scans were done over a
three-month interval in this patient and
there was no evidence of metastases.
She was not jaundiced when the alkaline phosphatase was markedly elevated.

liver, duodenum, renal pelvis and
uterine tube, one each. With the exception of two patients with adenocarcinoma of the colon all of these patients
were jaundiced at or near the time
when the serum alkaline phosphatase
was extremely high. Nineteen of the 21
patients have since died and nine had
post mortem examinations. Three of
these had hepatic abscesses, as well as
malignancy metastatic to the liver or
porta hepatis. None of the 21 patients
had extensive bone metastases and,
when these were present, they were
not osteoblastic.
Of the 14 patients with nonmalignant disease to account for the high
serum alkaline phosphatase, two had
primary biliary cirrhosis, two had secondary biliary cirrhosis and one had
portal cirrhosis. Extrahepatic bile duct
obstruction was responsible in three,
and drug-induced cholestasis was
thought to be the cause in the other six.
In one this was considered due to chlorpromazine and in another to novobiocin. One young woman developed jaundice and high serum alkaline phosphatase levels while taking a contraceptive
drug containing an estrogen and a progestogen. These levels promptly subsided upon discontinuance of the drug.
No single drug could be implicated in
three patients who were taking several
medications.

In 35 of the 45 patients, the high
phosphatase was attributed to liver
and/or biliary tract disease. Malignant
disease involving the liver and/or the
extrahepatic biliary system was the
cause in 21 patients. These cancers
were primary in the following sites:
colon and rectum, 7; pancreas, 3;
stomach, 2; breast, 2; and gallbladder,
ampulla of Vater, common bile duct.

One of these, a 49-year-old woman
with chronic pyelonephritis and renal
failure, became jaundiced and had
high serum alkaline phosphatase levels
during the final eight days of her life.
No extrahepatic biliary tract obstructive disease and no malignancy were
seen at necropsy. There was no evidence of secondary hyperparathyroidism and no significant bone disease.
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The second, a 70-year-old woman
with Hodgkin's disease, developed
jaundice and had a serum alkaline
phosphatase of 76 Bodansky units/100
ml while receiving a variety of drugs.
The abnormal bilirubin and phosphatase measurements promptly returned
to normal after several of the drugs
were stopped. Eleven months following the episode of jaundice, she was
feeling well, with the Hodgkin's disease
apparently under control.
A 64-year-old man with sarcoidosis,
the final case, presented with jaundice
and elevated serum alkaline phosphatase. No gross liver disease was seen
at the time of a common bile duct
exploration. The jaundice gradually
subsided over a period of several weeks,
although the serum alkaline phosphatase continued to be modestly elevated.
In this patient, the hyperbilirubinemia

and high phosphatase were thought due
to a toxin, probably a drug.
Comment
The underlying disease processes responsible for extremely high serum alkaline phosphatase activities are probably not different from those that cause
more modest elevations of this enzyme.
Pathologic conditions likely to be the
cause are Paget's disease of bone,
osteoblastic bone metastases, active
rickets,'' primary and metastatic tumors
of the liver, hepatic abscesses, granulomatous diseases of the liver and
hepatic amyloidosis.'' The present study
indicates that other causes may be druginduced cholestasis, non-malignant extrahepatic bile duct obstruction, some
forms of cirrhosis and primary hyperparathyroidism with osteitis fibrosa.
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